ALACT — Acticor Biotech SA Income Statement
0.000.00%
Last trade - 00:00- €3.30m
- €5.73m
Annual income statement for Acticor Biotech SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 5.17 | 7.58 | 11.9 | 15.1 | 17.6 |
| Operating Profit | -5.17 | -7.58 | -11.9 | -15.1 | -17.6 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -5.25 | -7.65 | -12.6 | -15.9 | -18.6 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -5.05 | -7.65 | -12.6 | -15.9 | -18.6 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -5.05 | -7.65 | -12.6 | -15.9 | -18.6 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -5.05 | -7.65 | -12.6 | -15.9 | -18.6 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.479 | -0.726 | -1.62 | -1.51 | -1.54 |
| Dividends per Share |